In non-small cell lung cancer (NSCLC), according to the NCCN Guidelines (version 1.2022) (3) and the Japanese Lung Cancer Society Guidelines for NSCLC (2021 edition) (4), combination therapy with an anti-PD-1/PD-L1 antibody and platinum-based chemotherapy is recommended as first-line therapy for patients with advanced NSCLC without driver gene mutations. This evidence concerns the gene CD274 and lung carcinoma.